3 Shares For Your 2015 ISA: Lloyds Banking Group PLC, AstraZeneca plc And Barratt Developments Plc

Lloyds Banking Group PLC (LON: LLOY), AstraZeneca plc (LON: AZN) and Barratt Developments Plc (LON: BDEV) could get your 2015 ISA off to a great start.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

April brings our new 2015 ISA allowances, with a modest rise from last year’s £15,000 to £15,240. At the moment, the very best cash ISAs around would earn you about £240 in interest, and you should easily be able to beat that with shares. Here are three for you to consider:

Lloyds

Lloyds Banking Group (LSE: LLOY)(NYSE: LYG.US) recently announced its return to paying dividends — a yield of less than 1% for 2014, but the occasion was momentous nonetheless. Forecasts suggest a decent yield of 3.6% for this year, followed by 5.2% in 2016, and that’s serious cash again.

In fact, a yield of 5.2% extended to your entire ISA allowance would provide £792 in dividend cash alone — more than three times the interest on a cash ISA.

With profits back and liquidity ratios strengthening, Lloyds shares are on a forward P/E of only 10, dropping a little for 2016. That’s significantly cheaper than bailed-out rival Royal Bank of Scotland, which is at least a year behind in resuming dividend payments. Lloyds looks like a bargain to me.

AstraZeneca

If you want to see a terrific turnaround, look no further than what CEO Pascal Soriot has achieved at AstraZeneca (LSE: AZN)(NYSE: AZN.US). The FTSE 100 pharmaceutical company was struggling with loss of patent protection, a weak development pipeline, and plunging profits just a few short years ago.

Yet by refocusing on the company’s key strengths, offloading non-core businesses, and reinvesting in research and development, Mr Soriot has returned AstraZeneca’s pipeline to one of the best in the business, and we’re expecting a return to earnings growth by 2017 at the latest.

And while we’re waiting for that, there’s a 4.1% dividend yield on the cards, and it should be covered well enough to be safe.

Barratt

Does it make sense to buy a housebuilder that’s already climbed 17% in the past year and has more than quadrupled over five years? It’s Barratt Developments (LSE: BDEV), and I reckon it does.

For the year to June 2015, the City is expecting another 38% EPS rise from Barratt, followed by 18% in 2016. That’s slower than the meteoric earnings growth of recent years, but it would still leave the shares on a 2016 P/E of only around 10 — that really does show just how undervalued the housebuilding sector was at the depths of the recession.

Longer term growth seems pretty much assured too, as the UK’s housing shortage continues to bite and political parties are vying to make the best promises of boosting building. There were no dividends during the slump, but Barratt is on for a 4.4% yield this year followed by 5.4% next, and that looks very attractive to me.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

The best time to buy stocks? It might be right now

Short-term issues that delay long-term trends create opportunities to buy stocks. And that could be happening right now with a…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Here’s why Next stock rose 5% and topped the FTSE 100 today

Next was the leading FTSE 100 stock today, rising 5%. Our writer takes a look at why and asks if…

Read more »

Renewable energies concept collage
Investing Articles

Up 458% in a year, could the Ceres Power share price go even higher?

Christopher Ruane reviews some highs and lows of the Ceres Power share price over the years and wonders whether the…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Are the glory days over for Rolls-Royce shares?

Rolls-Royce shares have soared in recent years. Lately, though, they have taken a tumble. Could there be worse still to…

Read more »

Group of friends meet up in a pub
Investing Articles

Are ‘66% off’ Diageo shares a once-in-a-decade opportunity?

Diageo shares have taken another hit in the early weeks of 2026. Are we looking at a massive bargain or…

Read more »

Investing Articles

Meet the UK stock under £1.50 smashing Rolls-Royce shares over the past year

While Rolls-Royce shares get all the attention, this under-the-radar trust has quietly made investors a fortune. But is it still…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Down 19%, the red lights are flashing for Barclays shares!

Barclays shares have fallen almost a fifth in value as the Middle East war has intensified. Royston Wild argues that…

Read more »

Aviva logo on glass meeting room door
Investing Articles

After falling another 5%, are Aviva shares too cheap to ignore?

£10,000 invested in Aviva shares five years ago would have grown 50% by now. But what might the future hold,…

Read more »